Latest news Diaccurate Announces Updated Data on its Novel PAM Pathway Inhibitor DIACC3010 in Patients with ER+ HER2- Metastatic Breast Cancer to be Presented at AACR 2023 April 6, 2023 Diaccurate receives support from Bpifrance to conduct its DIACC2020 Program on the development of new payloads for antibody-drug conjugates (ADCs) January 5, 2023 Diaccurate welcomes to its Board of Directors Prof. Karine Lacombe, internationally renowned infectious disease specialist and Dr. Catherine George, expert in early drug development June 24, 2022 See all press releases Home Media Selected media Diaccurate Adds Merck PAM Inhibitor to Oncology/Immunology Pipeline September 9, 2021 Merck KGaA entrusts secretive startup with a mid-stage cancer drug targeting master signaling pathway September 8, 2021 Could HIV be cured by tackling ‘bumpy’ CD4 cells? France’s Diaccurate wants to find out August 12, 2021 Media contact details MC Services (US & EU) Anne Hennecke +49 211 529252 22 Simone Neeten +49 211 52925217 diaccurate@mc-services.eu ATCG Partners (France) Marie Puvieux +33 (0)9 52 78 85 08 diaccurate@atcg-partners.com
Diaccurate Announces Updated Data on its Novel PAM Pathway Inhibitor DIACC3010 in Patients with ER+ HER2- Metastatic Breast Cancer to be Presented at AACR 2023 April 6, 2023
Diaccurate receives support from Bpifrance to conduct its DIACC2020 Program on the development of new payloads for antibody-drug conjugates (ADCs) January 5, 2023
Diaccurate welcomes to its Board of Directors Prof. Karine Lacombe, internationally renowned infectious disease specialist and Dr. Catherine George, expert in early drug development June 24, 2022
Merck KGaA entrusts secretive startup with a mid-stage cancer drug targeting master signaling pathway September 8, 2021
Could HIV be cured by tackling ‘bumpy’ CD4 cells? France’s Diaccurate wants to find out August 12, 2021
